Lisa is an SVP & Chief Marketing Officer at Lifescan, leading the successful commercialization of digital health platforms and blood glucose monitoring technologies by working cross-functionally and with Lifescan’s partners. She attended the University of Michigan and earned her MBA in Marketing and Corporate Strategy. Most recently, Lisa was the Chief Marketing and Innovation Officer for Vyaire Medical responsible for growing the respiratory business with innovative new products and leading the Marketing, Business Development, R&D, Regulatory Affairs and Medical Affairs organizations. Previously, as Divisional Vice President and Head of Global Marketing for Abbott Diagnostics, Lisa led blockbuster global platform and professional services launches and built market-leading brand reputation strategies. Prior to her tenure with Abbott, Lisa spent 15 years in senior marketing leadership roles across several different businesses with Novartis and Procter & Gamble.

Julio Rosenstock, MD Dallas Diabetes Research Center at Medical City and University of Texas Southwestern Medical Center, Dallas, USA Julio Rosenstock is Director of the Dallas Diabetes Research Center at Medical City, and Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Dallas. He received his MD from the University of Costa Rica School of Medicine and completed fellowships in Endocrinology and Diabetes at the Royal Postgraduate Medical School, Hammersmith Hospital, London, UK, and at the University of Texas Southwestern Medical Center. He is board certified in Internal Medicine, and Endocrinology and Metabolism. His clinical and research activities have focused on exploring novel agents and therapeutic strategies to improve glycemic control, particularly early insulin intervention with combination strategies in Type 2 Diabetes. Over the last 30 years, he has participated in hundreds of clinical trials and has had an active role in the development of new oral agents and insulin preparations acting often as a lead clinical investigator and scientific advisor. Dr Rosenstock has been the author or co-author of 345 peer-reviewed manuscripts (H-index 108) and several hundreds of scientific abstracts. He has also contributed to 13 book chapters on various topics in the field of diabetes. He is considered a key opinion leader in Type 2 Diabetes as reported in: (http://www.expertscape.com/ex/diabetes+mellitus+type+2/c/us). He is currently Associate Editor of Diabetes Care and an active reviewer for several journals. Dr Rosenstock has chaired or been a featured speaker at multiple lectures and presentations both nationally and internationally.

Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes. Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing has in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis. He was coordinator of the EU FP7 project PRIORITY demonstrating that urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy. He has co-authored >550 papers and his h-index is 79. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD and the E. Bierman award from ADA. Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry.

Luis Ruiz-Valdepeñas Martín de Almagro is the R&D director of Insulcloud. He studied Physics and holds a PhD in Physics by UCM (Universidad Complutense de Madrid) with two patents and five publications. Works in R&D developments since 2007 and in Insulcloud SL since 2015. Experience in designing technology-based business development projects, obtaining national and European R&D financing instruments and in quality assurance from the point of view of the R&D and the design history file..

Steven Jon Russell, MD, PhD Dr. Russell is an Associate Professor of Medicine at Harvard Medical School and an Associate Physician at Massachusetts General Hospital Diabetes Research Center. He completed medical and doctoral (MD/PhD) training at University of Texas Southwestern Medical School and a residency in Internal Medicine and fellowship in Endocrinology at the Massachusetts General Hospital. He is board certified in Endocrinology, Diabetes & Metabolism. Dr. Russell has been the principal clinical investigator of a collaboration between Massachusetts General Hospital and Boston University to develop a wearable bionic pancreas system for automated glycemic management in people with diabetes mellitus. The technology has been licensed to Beta Bionics, a public benefit corporation, for further development and commercialization in the form of the iLet bionic pancreas. Dr. Russell is the Study Director for the iLet Pivotal Trials. His other projects include evaluation of continuous glucose monitoring technology, methods for automated management of glucose in hospitalized patients, investigations of methods to improve insulin pharmacokinetics, investigations of stable formulations of glucagon, and development of a device for minimally invasive continuous insulin monitoring. Dr. Russell’s research has been supported by the National Institutes of Health (NIH), The Leona M. and Harry B. Helmsley Charitable Trust, the Banting Foundation, the American Diabetes Association, and the Juvenile Diabetes Research Foundation.